MedTrace Logo

Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections

NCT03510351 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-05-22

No results posted yet for this study

Summary

This study will describe clinical outcomes in patients who received ceftolozane-tazobactam for a Pseudomonas aeruginosa infection. Primary outcomes include 30-day and in-hospital mortality.

Conditions

  • Pseudomonas Infections
  • Pseudomonas Aeruginosa

Interventions

DRUG

Ceftolozane-Tazobactam

Subjects treated with ceftolozane-tazobactam for Pseudomonas infections

Sponsors & Collaborators

  • Temple University

    lead OTHER

Principal Investigators

  • Peter Doukas, Ph.D · Temple University - School of Pharmacy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2018-02-28
Completion
2018-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03510351 on ClinicalTrials.gov